Exelixis
EXEL
₹3,038
Share price
2.47%
Change (1 day)
60.95%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Revenue for Exelixis (EXEL)
Revenue in 2024 (TTM): ₹182.36 Billion
According to Exelixis's latest financial reports the company's current revenue (TTM 
) is ₹186.61 Billion. an increase over the revenue in the year 2023 that were of ₹152.36 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exelixis from 2000 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | ₹186.04 B | 22.11% |
| 2023 | ₹152.36 B | 14.29% |
| 2022 | ₹133.31 B | 24.82% |
| 2021 | ₹106.80 B | 47.89% |
| 2020 | ₹72.22 B | 4.65% |
| 2019 | ₹69.01 B | 15.6% |
| 2018 | ₹59.70 B | 106.64% |
| 2017 | ₹28.89 B | 122.06% |
| 2016 | ₹13.01 B | 426.67% |
| 2015 | ₹2.47 B | 55.22% |
| 2014 | ₹1.59 B | -17.8% |
| 2013 | ₹1.93 B | -25.48% |
| 2012 | ₹2.59 B | -83.04% |
| 2011 | ₹15.32 B | 84.78% |
| 2010 | ₹8.29 B | 17.76% |
| 2009 | ₹7.04 B | 24.3% |
| 2008 | ₹5.66 B | 27.21% |
| 2007 | ₹4.45 B | 1.9% |
| 2006 | ₹4.37 B | 27.85% |
| 2005 | ₹3.41 B | 49.33% |
| 2004 | ₹2.28 B | -2.45% |
| 2003 | ₹2.34 B | 10.41% |
| 2002 | ₹2.12 B | 7.42% |
| 2001 | ₹1.97 B | 71.23% |
| 2000 | ₹1.15 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | ₹3.457 T | 1,752.75% | 🇬🇧 UK |
 | ₹4.126 T | 2,111.48% | 🇫🇷 France |
 | ₹5.521 T | 2,858.82% | 🇺🇸 USA |
 | ₹4.156 T | 2,127.14% | 🇺🇸 USA |
 | ₹2.876 T | 1,441.20% | 🇺🇸 USA |
 | ₹7.643 T | 3,995.59% | 🇺🇸 USA |
 | ₹5.475 T | 2,833.83% | 🇺🇸 USA |
 | ₹0.93 B | -99.50% | 🇺🇸 USA |
 | ₹8.11 B | -95.65% | 🇺🇸 USA |